Trial Condition(s):
Pneumonia
Community-Acquired Pneumonia (CAP) surveillance
Bayer Identifier:
15465
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.
Inclusion Criteria
- Chinese adult (male or female) ≥18 years old - Outpatients or inpatients who suffer from CAP
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
560
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
No Drug
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
| Locations | |
|---|---|
Locations Investigative Site Many Locations, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Community-Acquired Pneumonia (CAP) Mycoplasma Surveillance
Trial Type:
Observational
Intervention Type:
Other
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- In vitro Minimal Inhibitory Concentration DetectionTimeframe: Up to 27 months
Secondary Outcome
- In vitro Gene Mutation DetectionTimeframe: Up to 15 months
Additional Information
Copyright © Bayer
Powered by
